No Data
Akeso Reports FY Results
BeiGene Secures Positive CHMP Opinion For TEVIMBRA As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer
The optimization policy direction for drug central purchasing is a hot topic: overcoming the "Low Stock Price" phenomenon and guiding quality supervision.
① The government work report on March 5 mentioned the need to "optimize the Pharmaceutical and consumables centralized procurement policy"; ② From the overall trend of optimizing the centralized procurement policy, there is a greater emphasis on moderate price reductions and quality supervision, and the concentration of the Industry is expected to further increase.
AKESO: The sharp decline in commercialization licensing revenue has led to a shift from profit to loss, while sales of Innovative Drugs continue to grow rapidly | Interpretations
① Due to a significant decrease in commercial revenue, AKESO is expected to turn from profit to loss in 2024. ② The commercialization of Innovative Drugs is continuously being promoted, and sales revenue is maintaining rapid growth.
BD Trade resolves financing difficulties! Industry: Innovative Drugs have survived, but the challenge of thriving is even greater.
① In 2024, license-out Trade has become an important way for Biotech to recover funds and increase revenue; ② The quality and standing of Innovative Drugs in China are gaining more international recognition; ③ Whether Innovative Drugs are worth investing in is related to the secondary market in the short term, but in the medium to long term, it depends on the improvement of the primary market exit channels, the payment environment for Innovative Drugs, and other issues.
Zai Lab Shares Are Trading Higher on Possible Continued Strength After the Company Announced Yesterday That It Will Present New Data for Oncology Candidates at the Upcoming Annual 2025 American Association For Cancer Research. Additionally, Cantor...